SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-061828
Filing Date
2022-03-02
Accepted
2022-03-01 20:02:06
Documents
14
Period of Report
2022-03-01
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d292261d8k.htm   iXBRL 8-K 25208
2 EX-99.1 d292261dex991.htm EX-99.1 26603
6 GRAPHIC g292261g0302001410781.jpg GRAPHIC 3014
  Complete submission text file 0001193125-22-061828.txt   187363

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ctic-20220301.xsd EX-101.SCH 2871
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ctic-20220301_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ctic-20220301_pre.xml EX-101.PRE 11271
8 EXTRACTED XBRL INSTANCE DOCUMENT d292261d8k_htm.xml XML 3434
Mailing Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121
Business Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121 2062827100
CTI BIOPHARMA CORP (Filer) CIK: 0000891293 (see all company filings)

IRS No.: 911533912 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-28386 | Film No.: 22700729
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences